MDR-TB Risk Assessment: Identifies patients requiring rapid molecular resistance testing. Drug-susceptibility testing (DST) is gold standard.
Treatment Failure
Positive culture @ month 5
Relapse
Positive after declared cured
Return after Default
Interruption ≥ 2 months
Management Recommendation
Standard TB workup recommended. Drug resistance is unlikely but clinical monitoring continues.